Jyong Biotech (MENS) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Veraxa Biotech (VRXA) has outperformed Jyong Biotech (MENS) over the past year, losing 88.5% versus a loss of 96.3%. Veraxa Biotech is the larger company by market cap ($157.0 million vs $154.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | VRXA |
|---|---|---|
| Share price | $2.03 | $1.11 |
| Market cap | $154.34M | $156.96M |
| 1-day change | -0.98% | -7.32% |
| YTD return | -47.85% | -88.75% |
| 1-year return | -96.26% | -88.53% |
| EPS (TTM) | $-0.06 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $63.00 | $27.36 |
| 52-week low | $1.43 | $1.04 |
| Distance from 52-week high | -96.78% | -95.94% |
| Average volume | 46.10K | 274.75K |
| Shares outstanding | 74.23M | 141.41M |
| Employees | 27 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
MENS vs VRXA FAQ
Which is bigger, Jyong Biotech or Veraxa Biotech?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $156.96M compared with $154.34M for Jyong Biotech (MENS).
Which stock has performed better over the past year, MENS or VRXA?
VRXA returned -88.53% over the past 12 months, compared with -96.26% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.